Eyepoint Pharmaceuticals Inc
$ 13.58
0.59%
29 May - close price
- Market Cap 1,131,858,000 USD
- Current Price $ 13.58
- High / Low $ 14.02 / 13.48
- Stock P/E N/A
- Book Value 0.40
- EPS -3.51
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.54 %
- ROE -1.03 %
- 52 Week High 19.11
- 52 Week Low 7.11
About
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$37.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-07 | 2024-05-08 | 2024-03-07 | 2023-11-01 | 2023-08-02 |
| Reported EPS | -0.99 | -0.81 | -0.85 | -0.85 | -0.65 | -0.64 | -0.54 | -0.58 | -0.55 | -0.33 | -0.33 | -0.61 |
| Estimated EPS | -0.81 | -0.7477 | -0.77 | -0.8 | -0.69 | -0.4765 | -0.54 | -0.51 | -0.42 | -0.49 | -0.51 | 0.37 |
| Surprise | -0.18 | -0.0623 | -0.08 | -0.05 | 0.04 | -0.1635 | 0 | -0.07 | -0.13 | 0.16 | 0.18 | -0.98 |
| Surprise Percentage | -22.2222% | -8.3322% | -10.3896% | -6.25% | 5.7971% | -34.3127% | 0% | -13.7255% | -30.9524% | 32.6531% | 35.2941% | -264.8649% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.94 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EYPT
2026-05-24 01:11:11
Quantitative Research Desk analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), noting weak near and mid-term sentiment, but a strong long-term outlook. The report highlights a significant 75.5:1 risk-reward setup, targeting a 23.6% gain with minimal risk, and outlines three distinct AI-generated trading strategies. These strategies – Position Trading, Momentum Breakout, and Risk Hedging – offer specific entry, target, and stop-loss levels.
2026-05-19 10:39:45
EyePoint, Inc. (Nasdaq: EYPT) announced its participation in three upcoming investor conferences: Stifel 2026 Virtual Ophthalmology Forum, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. Management will provide fireside chats at each event in late May and early June 2026. The company is developing DURAVYU™, an investigational sustained delivery treatment for serious retinal diseases, with topline data for wet AMD expected in mid-2026.
2026-05-19 10:38:51
EyePoint, Inc. (Nasdaq: EYPT) announced its participation in three upcoming investor conferences: the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026; the Jefferies Global Healthcare Conference on June 3, 2026; and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The company will conduct fireside chats at each event, with webcasts available through its investor relations website. EyePoint is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials for wet AMD and DME.
2026-05-19 10:38:51
EyePoint (Nasdaq: EYPT) announced that its management will participate in three upcoming investor conferences. The company will hold fireside chats at the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference in late May and early June 2026. Webcasts and replays of these events will be available on EyePoint's investor relations website.
2026-05-19 07:38:51
EyePoint, Inc. announced the granting of non-statutory stock options to eight new employees as inducement awards, totaling 158,100 shares. These grants comply with NASDAQ Listing Rule 5635(c)(4), with an exercise price of $12.35 per share, vesting over four years. The company is focused on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials.
2026-05-18 11:10:01
EyePoint, Inc. announced the granting of non-statutory stock options to eight new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover an aggregate of 158,100 shares of EyePoint common stock, with an exercise price of $12.35 per share. The awards vest over four years, subject to continued employment, and are intended to attract and retain talent for the company, which focuses on developing therapeutics for serious retinal diseases.
